Clinical characteristics of ocular angiomatosis in von Hippel-Lindau disease and correlation with germline mutation

Archives of Ophthalmology

Volumn 117, Issue 3, 1999, Pages 371-378

  Webster, Andrew R ^a,b   Maher, Eamonn R ^b,c   Moore, Anthony T ^a  

^a ADDENBROOKE S HOSPITAL   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADULT; AGED; ANGIOMA; ARTICLE; CLINICAL FEATURE; FEMALE; GENE MUTATION; HEMANGIOBLASTOMA; HEMANGIOMATOSIS; HETEROZYGOTE; HUMAN; MALE; PREVALENCE; PRIORITY JOURNAL; RETINA DETACHMENT; RETINA HEMORRHAGE; RETINA NEOVASCULARIZATION; SCHOOL CHILD; SURVIVAL; VISUAL IMPAIRMENT; VITREOUS HEMORRHAGE; VON HIPPEL LINDAU DISEASE;

EID: 0033037128     PISSN: 00039950     EISSN: None     Source Type: Journal    
DOI: 10.1001/archopht.117.3.371     Document Type: Article

References (27)

1. Maher ER, Iselius L, Yales JRW, et al. Von Hippel-Lindau disease: a genetic study. J Med Genet. 1991;28:443-447.
2. von Hippel E. Uber eine sehr seltene erkrankung der netzhaut. Graefes Arch Ophthalmo. 1904;59:83-106.
3. Welch RB. van Hippel-Lindau disease: the recognition and treatment of early angiomatosis retinae and the use of cryosurgery as an adjunct to therapy. Trans Am Ophthalmol Soc. 1970;68:367-424.
4. Shields JA, Decker WL, Sanborn GE, Augsburger JJ, Goldberg RE. Presumed acquired retinal hemangiomas. Ophthalmology. 1983;90:1292-1300.
5. Welch RB. In discussion of: Shields JA, Decker WL, Sanborn GE, Augsburger JJ, Goldberg RE. Presumed acquired retinal hemangiomas. Ophthalmology. 1983; 90:1300.
6. Welch RB. In discussion of: McDonald HR, Schatz H, Johnson RN, et al.Vitrectomy in eyes with peripheral retinal angioma associated with traction macular detachment. Ophthalmology. 1996;103:334-335.
7. Shields CL, Shields JA, Barren J, De Potter P. Vasoproliferative tumors of the ocular fundus: classification and clinical manifestations in 103 patients. Arch Ophthalmol. 1995;113:615-623.
8. Maher ER, Yates JR, Harries R, et al. Clinical features and natural history ot von Hippel-Lindau disease. Q J Med. 1990;77:1151-1163.
9. Huson SM, Harper PS, Hourihan MD, Cole G, Weeks RD, Compston DA. Cerebellar haemangioblastoma and von Hippel-Lindau disease. Brain. 1986;109(pt 6):1297-1310.
10. Moore AT, Maher ER, Rosen P, Gregor Z, Bird AC. Ophthalmological screening tor von Hippel-Lindau disease. Eye. 1991;5(pt 6):723-728.
11. Latif F, Tory K, Gnarra J, et al. Identification of the von Hippel-Lindau disease tumor suppressor gene. Science. 1993;260:1317-1320.
12. Crossey PA, Richards FM, Foster K, et al. Identification of intragenic mutations in the von Hippel-Lindau disease tumor suppressor gene and correlation with disease phenotype. Hum Mol Genet. 1994;3:1303-1308.
13. Chen F, Kishida T, Yao M, et al. Germline mutations in the von Hippel-Lindau disease tumor suppressor gene: correlations with phenotype. Hum Mutat. 1995; 5:66-75.
14. Maher ER, Webster AR, Richards FM, et al. Phenotypic expression in von Hippel-Lindau disease: correlations with germline VHL gene mutations. J Med Genet. 1996;33:328-332.
15. Brauch H, Kishida T, Glavac D, et al. Von Hippel-Lindau (VHL) disease with pheochromocytoma in the Black Forest region of Germany: evidence for a founder effect. Hum Genet. 1995;95:551-556.
16. Richards FM, Crossey PA, Phipps ME, et al. Detailed mapping of germline deletions of the von Hippel-Lindau disease tumor suppressor gene. Hum Mol Genet. 1994;3:595-598.
17. Jones MH, Yamakawa K, Nakamura Y. Isolation and characterization of 19 dinucleotide repeat polymorphisms on chromosome 3p. Hum Mol Genet. 1992; 1:131-133.
18. Rosner B. Fundamentals of Biostatistics. 4th ed. Belmont, Calif: Wadsworth Publishing; 1995:chaps 8 and 10.
19. de Jong PTVM, Verkaart RJF, van de Vooren MJ, Majoor-Krakauer DF, Wiegel AR. Twin vessels in von Hippel-Lindau disease. Am J Ophthalmol. 1988;105: 165-169.
20. Schmidt D, Neumann HPH. Retinal vascular hamartoma in von Hippel-Lindau disease. Arch Ophthalmol. 1995;113:1163-1167.
21. Zbar B, Kishida T, Chen F, et al. Germline mutations in the von Hippel-Lindau disease (VHL) gene in families from North America, Europe, and Japan. Hum Mutat. 1996;8:348-357.
22. Knudson AG Jr. Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci U S A. 1971;68:820-823.
23. Prowse AH, Webster AR, Richards FM, et al. Somatic inactivation of the VHL gene in von Hippel-Lindau disease tumors. Am J Hum Genet. 1997;60:765-771.
24. Webster AR, Richards FM, MacRonald FE, Moore AT, Maher ER. An analysis of phenotypic variation in the familial cancer syndrome von Hippel-Lindau disease: evidence for modifier effects. Am J Hum Genet. 1998;63:1025-1035.
25. Siemeister G, Weindel K, Mohrs K, Barleon B, Martiny-Baron G, Marme D. Reversion of deregulated expression of vascular endothelial growth factor in human renal carcinoma cells by von Hippel-Lindau tumor suppressor protein. Cancer Res. 1996;56:2299-2301.
26. Wizigmann-Voos S, Breier G, Risau W, Plate KH. Up-regulation of vascular endothelial growth factor and its receptor in von Hippel-Lindau disease-associated and sporadic hemangioblastomas. Cancer Res. 1995;55:1358-1364.
27. Aiello LP. Vascular endothelial growth factor: 20th-century mechanisms, 21st-century therapies. Invest Ophthalmol Vis Sci. 1997;38:1647-1652.